ReviewCancer cell international2025
Recent clinical advances in nonconjugated antibodies and antibody-drug conjugates for colorectal cancer treatment.
Review in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The therapeutic potential of antibody-drug conjugates in advanced colorectal cancer: a systematic review and meta-analysis.Scientific reports · 2026Pooled it
- High INHBB expression in colorectal cancer is associated with poor prognosis and drives malignant phenotypes in tumor cells.Biology direct · 2026Article
- Antibody-Drug Conjugates: Pharmacotherapeutic Properties and Future Perspectives.Pharmaceutics · 2026Review
- Review
- Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib.Journal of clinical medicine · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe second most prevalent cause of cancer-related fatalities worldwide and the third most often diagnosed malignancy is colorectal cancer (CRC). The treatment of colorectal cancer has been transformed by recent developments in antibody-based therapeutics, such as antibody-drug conjugates (ADCs) and non-conjugated monoclonal antibodies (mAbs). This review aims to elucidate the most impactful therapeutic strategies in CRC immunotherapy, emphasizing both established and emerging approaches. MAIN BODY: With an emphasis on nonconjugated mAbs (such as bevacizumab and cetuximab) and ADCs (such as Ado-trastuzumab emtansine (T-DM1), Fam-trastuzumab deruxtecan), this study examines more than 150 clinical trials and peer-reviewed publications from sources including Scopus, PubMed, and Web of Science. The selection criteria included studies published within the last decade, emphasizing mechanisms of action, clinical efficacy, and safety profiles. Non-conjugated mAbs target specific tumor antigens to inhibit signaling pathways and stimulate immune-mediated cytotoxicity, while ADCs combine mAbs with cytotoxic payloads for precise tumor cell elimination. Clinical trials have demonstrated significant survival benefits with these agents in biomarker-selected populations, particularly in HER2-positive and microsatellite instability-high (MSI-H/dMMR) CRC subgroups. Challenges include drug resistance, variable antigen expression, and adverse effects, underscoring the need for biomarker-driven approaches and combination therapies.
conclusionsImmunotherapy, particularly non-conjugated mAbs and ADCs, transforms CRC treatment by improving survival and quality of life. Ongoing research is essential to address resistance mechanisms, optimize combination regimens, and integrate personalized therapies into clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.